[go: up one dir, main page]

DK3289876T3 - Forbindelser til behandling af cancer - Google Patents

Forbindelser til behandling af cancer Download PDF

Info

Publication number
DK3289876T3
DK3289876T3 DK17196904.1T DK17196904T DK3289876T3 DK 3289876 T3 DK3289876 T3 DK 3289876T3 DK 17196904 T DK17196904 T DK 17196904T DK 3289876 T3 DK3289876 T3 DK 3289876T3
Authority
DK
Denmark
Prior art keywords
cancer
compounds
treatment
Prior art date
Application number
DK17196904.1T
Other languages
English (en)
Inventor
Yan Lu
Wei Li
Duane D Miller
Zhao Wang
Jianjun Chen
James T Dalton
Chien-Ming Li
Original Assignee
Univ Tennessee Res Found
Univ Ohio State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tennessee Res Found, Univ Ohio State Res Found filed Critical Univ Tennessee Res Found
Application granted granted Critical
Publication of DK3289876T3 publication Critical patent/DK3289876T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK17196904.1T 2008-06-16 2009-06-16 Forbindelser til behandling af cancer DK3289876T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6187508P 2008-06-16 2008-06-16
EP09835407.9A EP2303021B1 (en) 2008-06-16 2009-06-16 Compounds for the treatment of cancer

Publications (1)

Publication Number Publication Date
DK3289876T3 true DK3289876T3 (da) 2022-10-10

Family

ID=41448223

Family Applications (3)

Application Number Title Priority Date Filing Date
DK17196904.1T DK3289876T3 (da) 2008-06-16 2009-06-16 Forbindelser til behandling af cancer
DK15168526.0T DK2959900T3 (da) 2008-06-16 2009-06-16 Forbindelse til behandling af cancer
DK09835407.9T DK2303021T3 (da) 2008-06-16 2009-06-16 Forbindelser til behandling af kræft

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK15168526.0T DK2959900T3 (da) 2008-06-16 2009-06-16 Forbindelse til behandling af cancer
DK09835407.9T DK2303021T3 (da) 2008-06-16 2009-06-16 Forbindelser til behandling af kræft

Country Status (22)

Country Link
US (2) US8592465B2 (da)
EP (3) EP3289876B1 (da)
JP (2) JP5507552B2 (da)
KR (4) KR20170128623A (da)
CN (2) CN104610230A (da)
AU (1) AU2009330686B2 (da)
CA (2) CA2962524C (da)
CY (2) CY1119217T1 (da)
DK (3) DK3289876T3 (da)
ES (3) ES2629927T3 (da)
HR (1) HRP20221086T1 (da)
HU (3) HUE060249T2 (da)
IL (2) IL209995A (da)
LT (3) LT2959900T (da)
MX (1) MX2010014066A (da)
PL (3) PL2303021T3 (da)
PT (3) PT2303021T (da)
RU (1) RU2514427C2 (da)
SI (1) SI3289876T1 (da)
TR (1) TR201903981T4 (da)
UA (1) UA105005C2 (da)
WO (1) WO2010074776A2 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3289876B1 (en) 2008-06-16 2022-07-20 University of Tennessee Research Foundation Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
AU2015227531B2 (en) * 2010-03-01 2017-03-02 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
RU2581367C2 (ru) * 2010-03-01 2016-04-20 Джи Ти Икс, ИНК. Соединения для лечения рака
MX336761B (es) * 2010-08-24 2016-01-29 Univ Tennessee Res Foundation Compuestos para el tratamiento de cancer.
CN104334545A (zh) 2012-03-16 2015-02-04 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
MX375059B (es) 2013-03-05 2025-03-06 Univ Tennessee Res Found Compuestos para el tratamiento de cancer.
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
EP3626717A1 (en) 2013-10-14 2020-03-25 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
KR102365952B1 (ko) 2013-10-14 2022-02-22 에자이 알앤드디 매니지먼트 가부시키가이샤 선택적으로 치환된 퀴놀린 화합물
WO2015115661A1 (ja) * 2014-02-03 2015-08-06 国立大学法人東京大学 アゾール誘導体骨格を有するペプチドの製造方法
WO2015171628A1 (en) * 2014-05-06 2015-11-12 Gtx, Inc. Compounds for treatment of cancer
EA201790082A1 (ru) 2014-07-03 2017-08-31 Селджен Квонтисел Рисёрч, Инк. Ингибиторы лизин-специфической демитилазы-1
WO2016106309A1 (en) 2014-12-23 2016-06-30 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
BR112017020900B1 (pt) 2015-03-30 2023-02-23 Mission Therapeutics Limited Compostos de 1-ciano-pirrolidina como inibidores de usp30 e seu uso, composição farmacêutica
CN107840842A (zh) 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
ES3008911T3 (en) 2017-07-11 2025-03-25 Vertex Pharma Carboxamides as modulators of sodium channels
AU2018334272B2 (en) 2017-09-15 2023-06-15 Forma Therapeutics, Inc. Tetrahydro-imidazo quinoline compositions as CBP/p300 inhibitors
CN108586443B (zh) * 2018-01-31 2019-11-26 佳木斯大学附属第一医院 一种防治支气管肺癌的药物及其制备方法
WO2019188456A1 (ja) * 2018-03-26 2019-10-03 学校法人 川崎学園 新規抗腫瘍剤
UA125551C2 (uk) 2018-05-15 2022-04-13 Юніверсіті Оф Теннессі Рісерч Фаундейшн Спосіб лікування тричі негативного раку молочної залози або раку яєчника
AU2019270091A1 (en) * 2018-05-15 2020-12-24 University Of Tennessee Research Foundation Compounds for treatment of pancreatic cancer
MX2020014303A (es) 2018-06-29 2021-03-25 Forma Therapeutics Inc Inhibición de la proteína de union a creb (cbp).
TW202102494A (zh) 2019-03-15 2021-01-16 美商弗瑪治療公司 抑制環amp-反應元件-結合蛋白(creb)
UY38979A (es) 2019-12-06 2021-07-30 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
EP4347031A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
CN113999149B (zh) * 2021-11-15 2024-04-02 沈阳药科大学 一种基于l-半胱氨酸合成二芳基硫醚类化合物的制备方法
JP2025512970A (ja) * 2022-04-07 2025-04-22 ヴェル インコーポレイテッド インフルエンザ及びポックスウイルス科ウイルス感染症の治療方法
WO2024229440A2 (en) * 2023-05-03 2024-11-07 Emory University Methods of treating cancer using mdm2 inhibitors and compositions related thereto
CN119409641A (zh) * 2024-11-05 2025-02-11 杭州电子科技大学 一种磺酰基衍生物和用途

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH528514A (de) 1969-05-22 1972-09-30 Bayer Ag Verfahren zur Herstellung von Acylimidazolen
US4721712A (en) 1984-06-12 1988-01-26 Pfizer Inc. 1,3-disubstituted 2-oxindoles as analgesic and anti-inflammatory agents
CN1030415A (zh) * 1987-02-20 1989-01-18 山之内制药株式会社 饱和的杂环碳酰胺衍生物和它的制备方法
DK1130017T3 (da) * 1990-11-30 2005-10-10 Otsuka Pharma Co Ltd Azolderivater og deres anvendelse som superoxidradikalinhibitorer
US5120749A (en) 1991-02-20 1992-06-09 Abbott Laboratories Platelet activating antagonists
GB2287196B (en) 1991-09-30 1995-11-15 Philip Richardson A surgical incision member for use in suturing
NO924963L (no) 1991-12-27 1993-06-28 Sankyo Co Pyridyltiazolidinkarboksylsyreamid-derivater og fremgangsmaate til fremstilling derav
JP3393891B2 (ja) 1992-08-18 2003-04-07 塩野義製薬株式会社 イミダゾール類の製造方法
US5514690A (en) 1992-11-17 1996-05-07 E. R. Squibb & Sons, Inc. Aminocarbonyl (thiocarbonyl) and cyanoguanidine derivatives of quinoline and indoline
JP2550915B2 (ja) 1994-06-21 1996-11-06 日本電気株式会社 印刷配線板の表面保護剤および表面保護膜の形成方法
KR100312471B1 (ko) 1994-12-15 2002-02-28 가와무라 요시부미 티아졸리디논화합물또는이를활성성분으로함유하는협심증치료제또는예방제
ES2158290T3 (es) 1995-03-02 2001-09-01 Sankyo Co Derivados de tiazolidinona opticamente activos.
JP2002515400A (ja) 1997-07-03 2002-05-28 ニューロジェン・コーポレーション ある種のジアリールイミダゾール誘導体；新規なクラスのｎｐｙ特異的リガンド
JP2004067510A (ja) 1997-12-26 2004-03-04 Mitsubishi Pharma Corp 新規イミダゾール誘導体
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
WO2001017992A1 (en) * 1999-09-09 2001-03-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JP2001240593A (ja) * 1999-10-12 2001-09-04 Japan Tobacco Inc 高トリグリセリド血症治療薬及び抗肥満薬
WO2001047875A1 (en) 1999-12-27 2001-07-05 Ortho-Mcneil Pharmaceutical, Inc. Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone
WO2001085685A1 (en) * 2000-05-11 2001-11-15 Consejo Superior Investigaciones Cientificas Heterocyclic inhibitors of glycogen synthase kinase gsk-3
PT1347971E (pt) 2000-12-21 2006-06-30 Bristol Myers Squibb Co Inibidores tiazolilicos de tirosina-cinases da familia tec
CA2443600A1 (en) * 2001-04-19 2002-10-31 Vertex Pharmaceuticals Incorporated Heterocyclyldicarbamides as caspase inhibitors
WO2003016338A1 (en) 2001-08-15 2003-02-27 Parker Hughes Institute Crystal structure of the btk kinase domain
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
PE20030547A1 (es) 2001-09-24 2003-08-18 Bayer Corp Derivados de imidazol para el tratamiento de la obesidad
US20040267017A1 (en) * 2001-09-26 2004-12-30 Bierer Donald E 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors
WO2003027085A2 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
EP1435951B1 (en) * 2001-10-12 2006-01-18 Bayer Pharmaceuticals Corporation Phenyl substituted 5-membered nitrogen containing heterocycles for the tretment of obesity
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
AU2002352706A1 (en) * 2001-11-15 2003-06-10 Maxia Pharmaceuticals, Inc. N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
PL372814A1 (en) * 2002-04-08 2005-08-08 Torrent Pharmaceuticals Ltd. Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
WO2003090680A2 (en) 2002-04-23 2003-11-06 Axys Pharmaceuticals, Inc. Novel phenyl derivatives as inducers of apoptosis
TW200404796A (en) * 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
AU2003293376A1 (en) 2002-12-10 2004-06-30 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
CA2515215A1 (en) 2003-02-10 2004-08-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP1594847A2 (en) 2003-02-12 2005-11-16 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
PL378919A1 (pl) 2003-04-10 2006-06-12 Avanir Pharmaceuticals Pochodne imidazolu do leczenia zaburzeń alergicznych i nadmiernego rozrostu
DE602004006852D1 (de) 2003-04-17 2007-07-19 Janssen Pharmaceutica Nv 2-phenyl-benzimidazol und 2-phenyl-imidazo-4,5ü-pyridin-derivate als checkpoint-kinase-cds1 (chk2)-hemmer zur behandlung von krebs
WO2004103959A2 (en) 2003-05-16 2004-12-02 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
US6787245B1 (en) 2003-06-11 2004-09-07 E. I. Du Pont De Nemours And Company Sulfonated aliphatic-aromatic copolyesters and shaped articles produced therefrom
CN1826310B (zh) 2003-07-24 2010-07-21 利奥制药有限公司 新的氨基二苯酮化合物
US7501538B2 (en) 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
US20060014740A1 (en) * 2003-11-18 2006-01-19 Miller Duane D Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof
EP1692121A1 (en) * 2003-11-18 2006-08-23 University of Tennessee Research Foundation Thiazolidinone amides, thiazolidine carboxylic acid amides, methods of making, and uses thereof
TW200529845A (en) * 2003-12-12 2005-09-16 Wyeth Corp Quinolines useful in treating cardiovascular disease
WO2005080367A1 (en) * 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
AU2005221138A1 (en) 2004-03-08 2005-09-22 Wyeth Ion channel modulators
JP2008503446A (ja) * 2004-05-06 2008-02-07 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤及びその使用
EP2027853A3 (en) 2004-06-18 2011-01-05 Agennix USA Inc. Kinase inhibitors for treating cancers
EP1781649B1 (en) * 2004-08-17 2008-08-13 F. Hoffmann-Roche AG Substituted hydantoins
US20060211603A1 (en) * 2004-08-18 2006-09-21 Vicuron Pharmaceuticals Inc. Ramoplanin derivatives possessing antibacterial activity
EP1627876A1 (en) 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
EP1637529A1 (en) * 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
MX2007006739A (es) * 2004-12-13 2007-08-02 Leo Pharma As Compuestos de aminobenzofenona sustituidos con triazol.
CN101137412B (zh) 2005-01-13 2012-11-07 布里斯托尔-迈尔斯·斯奎布公司 用作凝血因子XIa抑制剂的取代的二芳基化合物
CA2594860A1 (en) * 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
WO2006127587A1 (en) * 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
WO2008036067A2 (en) 2005-07-19 2008-03-27 The University Of Tennessee Research Foundation Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents
JP2009502816A (ja) 2005-07-29 2009-01-29 ４エスツェー アクチェンゲゼルシャフト 新規ヘテロ環状ＮＦ−κＢ阻害剤
AU2006301222A1 (en) * 2005-10-14 2007-04-19 Neurosearch A/S Imidazole derivatives for the treatment of anxiety and related diseases
CN101309912B (zh) * 2005-11-15 2013-09-25 大塚制药株式会社 噁唑化合物和药物组合物
KR101081293B1 (ko) 2006-01-18 2011-11-08 에프. 호프만-라 로슈 아게 11 베타-에이치에스디1 억제제로서 티아졸
US7612212B2 (en) 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
EP1832585A1 (en) 2006-03-10 2007-09-12 ORIDIS BIOMED Forschungs- und Entwicklungs GmbH Thiazole-piperidine derivatives for treatment of hyperproliferative diseases
EP1834954A1 (en) 2006-03-15 2007-09-19 4Sc Ag Thiazoles as NF-kB Inhibitors (proteasome inhibitors)
WO2007115805A2 (en) * 2006-04-05 2007-10-18 European Molecular Biology Laboratory (Embl) Aurora kinase inhibitors
WO2007146230A2 (en) 2006-06-14 2007-12-21 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
BRPI0712642A2 (pt) 2006-07-13 2012-05-29 Bayer Cropscience Sa "composto, composição fungicida, uso de um composto e método de controle curativo ou preventivo dos fungos fitopatogênicos"
PE20080948A1 (es) 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog
NZ596024A (en) * 2006-08-07 2013-07-26 Ironwood Pharmaceuticals Inc Indole compounds
EP2050749B1 (en) 2006-08-08 2017-11-22 Chugai Seiyaku Kabushiki Kaisha Pyrimidine derivative as pi3k inhibitor and use thereof
US20110172230A1 (en) 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
JP2010502706A (ja) * 2006-09-07 2010-01-28 ミレニアム・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害活性を有するフェネチルアミド誘導体
KR100932093B1 (ko) 2006-09-27 2009-12-16 주식회사종근당 미세소관 형성 저해제로서 유용한 벤조페논 유도체
US7795249B2 (en) 2006-12-22 2010-09-14 Millennium Pharmaceuticals, Inc. Certain pyrazoline derivatives with kinase inhibitory activity
WO2008128179A1 (en) 2007-04-14 2008-10-23 The University Of Tennessee Research Foundation Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents
US20090142832A1 (en) 2007-11-29 2009-06-04 James Dalton Indoles, Derivatives, and Analogs Thereof and Uses Therefor
WO2009076454A2 (en) 2007-12-12 2009-06-18 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP3289876B1 (en) 2008-06-16 2022-07-20 University of Tennessee Research Foundation Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9029408B2 (en) * 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
HRP20191617T1 (hr) 2009-10-16 2019-12-13 Novartis Ag Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
KR101134194B1 (ko) 2009-12-03 2012-04-09 서울대학교산학협력단 헤테로바이아릴피리딘 유도체 화합물의 제조방법 및 이러한 방법에 의해 제조된 헤테로바이아릴피리딘 유도체 화합물
RU2581367C2 (ru) 2010-03-01 2016-04-20 Джи Ти Икс, ИНК. Соединения для лечения рака
US8426418B2 (en) 2010-08-27 2013-04-23 CollabRx Inc. Method to treat melanoma in BRAF inhibitor-resistant subjects
US9348332B2 (en) 2011-03-29 2016-05-24 Mitsubishi Electric Corporation Abnormality diagnosis device and abnormality diagnosis system for servo control device
RS56759B2 (sr) 2011-04-01 2024-10-31 Genentech Inc Kombinacija akt inhibitor jedinjenja i abiraterona za upotrebu pri terapeutskim tretiranjima
US9206185B2 (en) 2011-04-07 2015-12-08 Bayer Intellectual Property Gmbh Imidazopyridazines as Akt kinase inhibitors
MX375059B (es) * 2013-03-05 2025-03-06 Univ Tennessee Res Found Compuestos para el tratamiento de cancer.

Also Published As

Publication number Publication date
CN102137592B (zh) 2015-01-28
DK2303021T3 (da) 2019-04-08
KR20170029031A (ko) 2017-03-14
CY1121724T1 (el) 2020-07-31
AU2009330686A1 (en) 2010-07-01
EP2959900A1 (en) 2015-12-30
HUE060249T2 (hu) 2023-02-28
UA105005C2 (uk) 2014-04-10
AU2009330686B2 (en) 2014-07-03
CY1119217T1 (el) 2018-02-14
PT2303021T (pt) 2019-04-01
ES2629927T3 (es) 2017-08-16
HUE043569T2 (hu) 2019-08-28
US10865196B2 (en) 2020-12-15
IL229878A (en) 2015-04-30
RU2514427C2 (ru) 2014-04-27
DK2959900T3 (da) 2017-06-26
LT3289876T (lt) 2022-11-10
JP2012162541A (ja) 2012-08-30
CA2962524C (en) 2020-07-14
US8592465B2 (en) 2013-11-26
EP2303021B1 (en) 2018-12-19
HRP20221086T1 (hr) 2022-11-25
LT2959900T (lt) 2017-09-25
KR20170128623A (ko) 2017-11-22
CA2728118C (en) 2018-01-16
EP2303021A4 (en) 2012-03-14
CA2962524A1 (en) 2010-07-01
PL2959900T4 (pl) 2017-11-30
JP2011524422A (ja) 2011-09-01
KR20160079934A (ko) 2016-07-06
IL209995A0 (en) 2011-02-28
IL209995A (en) 2014-05-28
PL2959900T3 (pl) 2017-11-30
JP5507552B2 (ja) 2014-05-28
IL229878A0 (en) 2014-01-30
KR20110022672A (ko) 2011-03-07
MX2010014066A (es) 2011-06-01
US20190092755A1 (en) 2019-03-28
PT2959900T (pt) 2017-06-22
WO2010074776A3 (en) 2010-08-19
CN102137592A (zh) 2011-07-27
CA2728118A1 (en) 2010-07-01
ES2715926T3 (es) 2019-06-07
PL3289876T3 (pl) 2022-11-21
PL2303021T3 (pl) 2019-10-31
CN104610230A (zh) 2015-05-13
US20090326020A1 (en) 2009-12-31
PT3289876T (pt) 2022-10-28
EP2303021A2 (en) 2011-04-06
EP3289876A1 (en) 2018-03-07
SI3289876T1 (sl) 2023-01-31
WO2010074776A2 (en) 2010-07-01
EP2959900B1 (en) 2017-03-08
LT2303021T (lt) 2019-06-25
RU2010154172A (ru) 2012-07-27
TR201903981T4 (tr) 2019-04-22
ES2927660T3 (es) 2022-11-10
HUE034598T2 (en) 2018-02-28
EP3289876B1 (en) 2022-07-20
KR102025213B1 (ko) 2019-09-25

Similar Documents

Publication Publication Date Title
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2195015T3 (da) Sammensætning til behandling af prostatacancer
DK3517534T3 (da) Forbindelser, der er anvendelige til behandling af cancer
DK2478907T3 (da) Sammensætninger til behandling af kræft
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
DK2076540T3 (da) Hidtil ukendte anti-cd38-antistoffer til behandling af cancer
DK2114886T3 (da) Fremgangsmåde til fremstilling af visse substituerede sulfiliminer
DK2498771T3 (da) Anvendelse af bethanechol til behandling af xerostomi
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
BRPI0908353A2 (pt) Compostos
DK2300443T3 (da) Triazolderivater, der er anvendelige til behandling af sygdomme
DK2452189T3 (da) Fremgangsmåde til identifikation af forbindelser til behandling af cancer
DK2117525T3 (da) Anvendelse af 1-phenyl-3-dimethylamino-propanforbindelser til behandling af neuropatismerte
DK2209784T3 (da) Forbindelser til behandling af hepatitis C
DK2451482T3 (da) Kombinationsterapi til behandlingen af diabetes
DK2162149T3 (da) Vaccine til forebyggelse af brystkræfttilbagefald
DK3246042T3 (da) Lægemiddelresistent immunterapi til behandling af cancer
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
DK3443957T3 (da) Forbindelser og sammensætninger til behandling af cancer
BRPI0922884A2 (pt) compostos para tratamento de câncer
DK2382232T3 (da) Fremgangsmåde til fremstilling af bivalirudin
BRPI0916432A2 (pt) compostos
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme